Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback